CAR-T– tag –
-
Max Delbrück Center Research Reveals ‘Quality Over Quantity’ in CAR-T Therapy, Identifying Key Factors for Low-Dose Efficacy to Enable Personalized Treatment and Cost Reduction
Max Delbrück Center for Molecular Medicine Germany Overview A research consortium from the Max Delbrück Center, publishing in "Nature Communications," identified key biological factors influencing CAR-T cell therapy effectiveness at lowe... -
UCLA Scientists Mass-Produce Ready-to-Use Cord Blood-Derived T Cells for Solid Tumors in 6 Weeks at $5,000/Dose, Avoiding GvHD Risk
UCLA USA Overview UCLA researchers have developed a platform to mass-produce cancer-fighting T cells from cord blood stem cells, engineered to target solid tumors. This innovative approach generates trillions of therapeutic cells (thousa... -
Next-Gen CAR-T Manufacturing Reduces Production Time to 1-2 Days, Explores Decentralized Models for Potent Cells
Bioprocess International USA Overview An article in Bioprocess International highlights advancements in next-generation CAR-T cell therapy manufacturing, which are set to reduce production times to as little as one or two days, yielding ... -
Leman Biotech Raises RMB 200M (USD 29M) Series A+ to Advance Ultra-Low-Dose Metabolically Armored CAR-T to Phase I Trials and Automated Manufacturing Scale-Up
Insight, China's Pharmaceutical Industry China Overview Leman Biotech has secured RMB 200 million (approximately USD 29 million) in Series A+ funding to advance Phase I trials of its ultra-low-dose metabolically armored CAR-T cell therap... -
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
Cell-Easy Expands Toulouse R&D to Scale Allogeneic NK Cell Therapy (10x Cost Reduction), Optimize G-Rex® CAR-T, and Advance iPSC-Derived Beta Cells
Cell-Easy (press release) France Overview Cell-Easy, a CDMO, announced the expansion of its Toulouse R&D facilities to accelerate three next-generation cell therapy manufacturing programs. The company aims for a ten-fold cost reducti... -
CAR-T Cell Therapy Manufacturing Breakthrough: Automated Bioreactors Cut Production Time Below 48 Hours, Reduce Costs by 35%
PMC USA Overview Recent research highlights significant advances in CAR-T cell therapy manufacturing, with automated bioreactors enabling point-of-care biomanufacturing that reduces cell product time to less than 48 hours and cuts costs ... -
Cell Therapy Startups Exceed $36 Billion in Cumulative Fundraising, Top Companies Secure Over $1 Billion Each
New Market Pitch United States Overview A report by New Market Pitch reveals that cell therapy startups have collectively surpassed $36 billion in cumulative fundraising by 2026, with leading companies each raising over $1 billion. The a... -
Typewriter Therapeutics Secures $56M Series A for In Vivo CAR-T, Aiming to Streamline Cell Therapy Manufacturing
BioBucks USA Overview Typewriter Therapeutics has raised $56 million in Series A funding to advance its innovative in vivo CAR-T cell therapy, designed to reprogram T cells directly within the patient's body. This approach eliminates the... -
BrainChild Bio Secures $116M, Earns FDA Breakthrough Designations for CAR-T Therapy Against Pediatric Brain Cancer DIPG
Hoodline USA Overview BrainChild Bio, a biotechnology firm spun out of Seattle Children's Hospital, has raised $116 million to advance its novel CAR-T cell therapy for Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brai...
